Evidence map›Paper›PMID 24802082›Full record

ArticlePloS one2014

Fatty acid binding protein 4 deficiency protects against oxygen-induced retinopathy in mice.

Magali Saint-Geniez, Elisa Ghelfi, Xiaoliang Liang, Chenwei Yu, Carrie Spencer, Stephanie Abend, Gokhan Hotamisligil, Sule Cataltepe

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases.Journal of atherosclerosis and thrombosis · 2019
    Review
  10. Article
  11. Review
  12. Article
  13. Tumors: wounds that do not heal-redux.Cancer immunology research · 2015
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Magali Saint-GeniezSchepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States of America.
Elisa GhelfiDepartment of Neonatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
Xiaoliang LiangDepartment of Neonatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
Chenwei YuDepartment of Neonatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
Carrie SpencerSchepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States of America.
Stephanie AbendSchepens Eye Research Institute, Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States of America.
Gokhan HotamisligilDepartment of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Sule CataltepeDepartment of Neonatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
Harvard University · USBrigham and Women's Hospital · USMassachusetts Eye and Ear Infirmary · USSmith-Kettlewell Eye Research Institute · US

Funding

PGC-1 coactivators in photoreceptor development and survivalR01EY023682 · NEI · UNIVERSITY OF PENNSYLVANIA · PI ARANY, ZOLTAN P, SAINT-GENIEZ, MAGALI · 2013 to 2015
$1.6M
Fatty Acid Binding Protein and Pathological Retinal VascularizationR21EY021873 · NEI · BRIGHAM AND WOMEN'S HOSPITAL · PI CATALTEPE, SULE, SAINT-GENIEZ, MAGALI · 2011 to 2012
$511k
NEI NIH HHS R01 EY023682NEI NIH HHS R21 EY021873
6 · The paper itself

Abstract

Retinopathy of prematurity (ROP) is a leading cause of blindness in children worldwide due to increasing survival rates of premature infants. Initial suppression, followed by increased production of the retinal vascular endothelial growth factor-A (VEGF) expression are key events that trigger the pathological neovascularization in ROP. Fatty acid binding protein 4 (FABP4) is an intracellular lipid chaperone that is induced by VEGF in a subset of endothelial cells. FABP4 exhibits a pro-angiogenic function in cultured endothelial cells and in airway microvasculature, but whether it plays a role in modulation of retinal angiogenesis is not known. We hypothesized that FABP4 deficiency could ameliorate pathological retinal vascularization and investigated this hypothesis using a well-characterized mouse model of oxygen-induced retinopathy (OIR). We found that FABP4 was not expressed in retinal vessels, but was present in resident macrophages/microglial cells and endothelial cells of the hyaloid vasculature in the immature retina. While FABP4 expression was not required for normal development of retinal vessels, FABP4 expression was upregulated and localized to neovascular tufts in OIR. FABP4-/- mice demonstrated a significant decrease in neovessel formation as well as a significant improvement in physiological revascularization of the avascular retinal tissues. These alterations in retinal vasculature were accompanied by reduced endothelial cell proliferation, but no effect on apoptosis or macrophage/microglia recruitment. FABP4-/- OIR samples demonstrated decreased expression of genes involved in angiogenesis, such as Placental Growth Factor, and angiopoietin 2. Collectively, our findings suggest FABP4 as a potential target of pathologic retinal angiogenesis in proliferative retinopathies.

Indexed as

AnimalsFatty Acid-Binding ProteinsMiceMice, Inbred C57BLNeovascularization, PathologicOxygenRetinal VesselsRetinopathy of PrematurityFabp4 protein, mouseFatty Acid-Binding ProteinsOxygen

Identifiers

PMID24802082
PMCPMC4011730
OpenAlexW2028358543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.